Announcements Trials
Browse Landscape

Phase

Phase 2 49Phase 1 25Phase 1/2 12Phase 3 10Phase 4 3Phase EARLY_PHASE1 2Phase 2/3 2

Status

Completed 2Active not recruiting 1

Sponsor Class

OTHER 1NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 1

Conditions

Hormone Receptor Positive HER-2 Negative Breast Cancer 1CCND1 Gene Amplification 1

Interventions

Cisplatin 22Fluorouracil 21Radiotherapy 18Gemcitabine 17Docetaxel 16Oxaliplatin 15Paclitaxel 14Carboplatin 13Capecitabine 13Bevacizumab 13Leucovorin 11Cyclophosphamide 11Irinotecan 10Drug Therapy 10Cytarabine 9Saline Solution 7Magnetic Resonance Spectroscopy 7Letrozole 7Dexamethasone 7Rituximab 6Nivolumab 6Methotrexate 6Exercise 6Etoposide 6Electroporation 6Doxorubicin 6pembrolizumab 5Pemetrexed 5Metformin 5Melphalan 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2/3 × Completed × palbociclib × Clear all
NCT02692755 2021-09-28

PALINA

Georgetown University

Phase 2/3 Completed
35 enrolled 12 charts
Breast

Hormone Receptor Positive HER-2 Negative Breast Cancer

NCT02785939 2021-05-27

Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer

SWOG Cancer Research Network

Phase 2/3 Completed
53 enrolled 15 charts

CCND1 Gene Amplification

Data powered by HemOnc (CC BY 4.0) Colophon âš¡